Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
Single component intervention showed no clear difference in adherence to pharmacotherapy: number of people completing treatment compared with control (low certainty).
It is very uncertain whether single component intervention changes hospital service utilisation: number of people admitted to hospital… compared with control (very low certainty).
It is very uncertain whether single component intervention changes exacerbations: number of people experiencing exacerbations compared with control (very low certainty).
It is very uncertain whether single component intervention changes adverse events: number of people experiencing adverse events (all… compared with control (very low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
Beta2‐agonists probably leads to lower number of participants with an FEV1 fall > 10% compared with placebo (single administration) (moderate certainty).
Beta2‐agonists showed no clear difference in side effects compared with placebo (single administration) (low certainty).